|
Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
DelSite
Biotechnologies, Inc.
(OTC: DSII)
Digital
Angel Corporation
(AMEX:DOC)
Duska Therapeutics,
Inc.
(OTC:DSKA)
Elan
Corporation
(NYSE: ELN)
Galapagos NV
(Euronext:GLPGA)
Intercell AG
(VSE:ICLL)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Lpath, Inc.
(OTC:LPTN)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware
Information Systems, Inc. (NASDAQ: MEDW)
Pipex Pharmaceuticals,
Inc.
(OTC:PPXP.OB)
Quidel
(NASDAQ:QDEL)
Redpoint Bio Corporation
(OTC:RPBC)
XTLbio
(NASDAQ:XTLB)
VIA Pharmaceuticals,
Inc.
(NASDAQ: VIAP)
ZIOPHARM, INC.
(NASDAQ:ZIOP)
| |
Pipex
Pharmaceuticals, Inc. ("Pipex") AMEX:PP is a development-stage,
specialty pharmaceutical company that is developing proprietary, late-stage
drug candidates for the treatment of central nervous system and autoimmune
diseases. Our strategy is to exclusively in-license proprietary, clinical-stage
drug candidates that have demonstrated clinical efficacy and to complete
the further clinical testing and manufacturing sufficient to seek marketing
authorizations via the filing of new drug applications (NDAs) with the FDA
and marketing application authorizations (MAAs) with the European Medicines
Evaluation Agency (EMEA).
COMPANY
NEWS | COMPANY
WEBSITE |SEC
FILINGS
|